As Originally Reported Under Asc 605 was Q32 Bio’s largest revenue line in fiscal 2018, bringing in $3.68M of $5.32M (69%).
| Initial Application Period Cumulative Effect Transition | FY 2018 |
|---|---|
| As Originally Reported Under Asc 605 | $3.68M |
| Effect Of Change | $1.64M |
| Total | $5.32M |
Q32 Bio brought in $5.32M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. As Originally Reported Under Asc 605 was the largest at $3.68M (69.2%), ahead of Effect Of Change at $1.64M (30.8%).
Q32 Bio (QTTB) reports its revenue by initial application period cumulative effect transition. In fiscal 2018, As Originally Reported Under Asc 605 was its largest revenue line, bringing in $3.68M (69.2% of the total), followed by Effect Of Change at $1.64M (30.8%).
As Originally Reported Under Asc 605 was Q32 Bio's largest revenue line in fiscal 2018, bringing in $3.68M, or 69.2% of the $5.32M total across its two revenue lines.
Every figure comes from Q32 Bio's annual financial filings, as reported. Each line keeps the name Q32 Bio gives it, and years follow its fiscal calendar.
Q32 Bio's revenue by initial application period cumulative effect transition goes back to fiscal 2018, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.